Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP) [2]

American Journal of Hematology

Volumn 77, Issue 1, 2004, Pages 103-104

  Swords, R ^a   Power, D ^a   Fay, M ^a   O'Donnell, R ^a   Murphy, P T ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL; IMMUNOGLOBULIN; PREDNISONE; RITUXIMAB; WARFARIN;

AGED; CASE REPORT; FEMALE; HEMATURIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTERSTITIAL PNEUMONIA; LETTER; PRIORITY JOURNAL; SPLENECTOMY; THROMBOCYTE COUNT;

EID: 4243132721     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20135     Document Type: Letter

References (3)

1. Mohit N, Penner JA, Williams D. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). Am J Hematol 2003;74:263-267.
2. Burton C, Kaczmarski R. Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003;348:2690-2691.
3. Giagounidis AAN, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-Cd monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002;69:95.